Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance

Amelie V. Guitart, Chithra Subramani, Alejandro Armesilla-Diaz, Gillian Smith, Catarina Sepulveda, Deniz Gezer, Milica Vukovic, Karen Dunn, Patrick Pollard, Tessa L. Holyoake, Tariq Enver, Peter J. Ratcliffe, Kamil R. Kranc

Blood (2013) 122 (10): 1741–1745.

https://doi.org/10.1182/blood-2013-02-484923

Published: 2013

Includes: Supplemental data

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

Journal Articles

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2010) 115 (12): 2364–2371.

https://doi.org/10.1182/blood-2009-04-217455

Published: 2010

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2009) 114 (22): 4062.

https://doi.org/10.1182/blood.V114.22.4062.4062

Published: 2009

Journal Articles

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2009) 114 (22): 5106.

https://doi.org/10.1182/blood.V114.22.5106.5106

Published: 2009

Journal Articles

Calibration of Improved T2* Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload.

Maciej W Garbowski, John-Paul Carpenter, Gillian Smith, Dudley J Pennell, John B Porter

Blood (2009) 114 (22): 2004.

https://doi.org/10.1182/blood.V114.22.2004.2004

Published: 2009

Journal Articles

Impact of Myocardial Iron Loading On Right Ventricular Function.

John-Paul Carpenter, Francisco Alpendurada, Monica Deac, Paul Kirk, John B Porter, J. Malcolm Walker, Winston Banya, Taigang He, Gillian Smith, Dudley J Pennell

Blood (2009) 114 (22): 2012.

https://doi.org/10.1182/blood.V114.22.2012.2012

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, John B Porter, Maria Domenica Cappellini, Chi-Kong Li, Yesim Aydinok, Chan Lee Lee, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2008) 112 (11): 3873.

https://doi.org/10.1182/blood.V112.11.3873.3873

Published: 2008

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, Pranee Sutcharitchan, Amal El-Beshlawy, Yesim Aydinok, Ali Taher, Gillian Smith, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 3874.

https://doi.org/10.1182/blood.V112.11.3874.3874

Published: 2008

NARROW

Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Calibration of Improved T2* Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload.

Impact of Myocardial Iron Loading On Right Ventricular Function.

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only